Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Huangao Zhu"'
Autor:
Qian Zhang, Yiqian Xing, Shan Jiang, Chunmei Xu, Xiaojun Zhou, Rui Zhang, Tianyue Xie, Zhiwei Zou, Piyun Gong, Huangao Zhu, Dongmei Zhang, Huimei Ma, Lin Liao, Jianjun Dong
Publikováno v:
Thoracic Cancer, Vol 11, Iss 2, Pp 336-345 (2020)
Background Differentiated thyroid cancer involves thyroid follicular carcinoma (FTC) and papillary thyroid carcinoma (PTC). Patients with FTC have a worse prognosis than those with PTC for early metastasis through blood of FTC. However, the mechanism
Externí odkaz:
https://doaj.org/article/936fa909c3574679ab172902fd58daf6
Autor:
Shan Jiang, Huimei Ma, Dongmei Zhang, Tianyue Xie, Ruzhen Zhang, Lin Liao, Huangao Zhu, Jianjun Dong, Rui Zhang, Chunmei Xu, Zhiwei Zou, Piyun Gong, Qian Zhang, Xiaojun Zhou
Publikováno v:
Journal of Cellular and Molecular Medicine
To explore the potential role of Lin28a in the development of restenosis after percutaneous transluminal angioplasty, double‐balloon injury surgery and mono‐balloon injury surgery were used to establish restenosis and atherosclerosis models, resp
Autor:
Xiaojun Zhou, Qian Zhang, Xianzhi Li, Tianyue Xie, Zhiwei Zou, Shan Jiang, Siyi Guo, Rui Zhang, Ruzhen Zhang, Piyun Gong, Huangao Zhu, Dongmei Zhang, Lin Liao, Jianjun Dong
Publikováno v:
SSRN Electronic Journal.
Background: The excessive proliferation and migration of VSMCs is the main cause of restenosis (RS). Our previous results suggested that overexpression of Lin28a is responsible for this “malignant” behaver of VSMCs. However, the mechanisms drivin
Autor:
Piyun Gong, Junyu Zhao, Qian-Zhang, Zhiwei Zou, Dongmei Zhang, Zhen-gang Guo, Huangao Zhu, Huimei Ma, Lin-Liao, Jianjun Dong, Zhao-shun Jiang
Publikováno v:
Lipids in Health and Disease
Lipids in Health and Disease, Vol 17, Iss 1, Pp 1-9 (2018)
Lipids in Health and Disease, Vol 17, Iss 1, Pp 1-9 (2018)
Background A low-protein diet (LPD) is believed to be beneficial in slowing the progression of kidney disease. It is reported that low protein diet can improve protein, sugar and lipid metabolism, and reduce the symptoms and complications of renal in
Publikováno v:
Thoracic Cancer
Background Vandetanib is the first US Food and Drug Administration approved agent to treat advanced or metastasized thyroid cancer. To gain a better understanding of the drug, we conducted a systematic review of its efficacy and safety in patients wi